Synergistic activity of trovafloxacin with other agents against Gram-positive and -negative organisms

Diagnostic Microbiology and Infectious Disease

Volumn 30, Issue 1, 1998, Pages 61-64

  Visalli, Melissa A ^a   Bajaksouzian, Saralee ^a   Jacobs, Michael R ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFOPERAZONE; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; FUSIDIC ACID; METRONIDAZOLE; RIFAMPICIN; TEICOPLANIN; TIMENTIN; TOBRAMYCIN; TROVAFLOXACIN; VANCOMYCIN;

BACTEROIDES FRAGILIS; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0031893353     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00166-1     Document Type: Article

References (10)

1. Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC. Activities of levofloxacin, ofloxacin and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother. 41:1997;1073-1076.
2. Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in vitro activity of CP-99,219, a new naphthyridone antimicrobial agent a comparison with fluoroquinolone agents . J Antimicrob Chemother. 35:1995;869-876.
3. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Agents Chemother. 37:1993;366-370.
4. Eliopoulos GM, Moellering RC Jr. Antimicrobial combinations. Lorian V. Antibiotics in Laboratory Medicine. 1996;330-396 Williams and Wilkins, Baltimore, MD.
5. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (Eds). (1995) Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology.
6. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Approved Standard M7-A4 . 1997;NCCLS, Villanova, PA.
7. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother. 35:1995;230-232.
8. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP-99,219 combined with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 38:1994;2471-2476.
9. Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 36:1995;385-394.
10. Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC. Comparative activity of trovafloxacin alone and in combination with other agents, against Gram-negative nonfermentative rods. Antimicrob Agents Chemother. 41:1997;1475-1481.